Abstract Gli1 is a transcription factor and oncogene with documented roles in the progression of several cancer types, including cancers of the skin and pancreas. The contribution of Gli1 to the progression of breast cancer is less established. In order to investigate the functional impact of Gli1 in breast cancer, expression of Gli1 and its contribution to cell growth was assessed in breast cancer cell lines. These in vitro results were compared to expression of Gli1, determined by immunohistochemistry, in 171 breast cancers. In these cancers, the association of Gli1 with expression of estrogen receptor a (ERa) and progesterone receptor (PR), ErbB2, p53, the rate of proliferation, and clinicopathologic parameters and outcome was assessed. Expression of Gli1 and ERa mRNA was strongly correlated in ERa-positive cell lines (r = 0.999). Treatment with estrogen increased expression of Gli1 in 2 of 3 ERa-positive cell lines; this increase was prevented by treatment with the ERa-specific antagonist MPP. Silencing of Gli1 by shRNA markedly reduced the survival of two ERa-negative cell lines, but caused only a modest reduction in ERa-positive cell lines. In breast cancer tissues, cancers with nuclear localization of Gli1 had a higher ERa (P=0.027) and lower p53 expression (P=0.017) than those without nuclear localization of Gli1. However, nuclear localization of Gli1 was predictive of a poorer cancerspecific survival in ERa-negative, including triple negative, cancers (P = 0.005), but not ERa-positive cancers. In conclusion, we demonstrate a positive association between expression of Gli1 and ERa; however, our data indicate a greater functional effect of Gli1 in ERa-negative cancers.
Introduction
Gli1 is a zinc finger transcription factor, an established oncogene, and a member of the vertebrate Gli family, which also includes Gli2 and Gli3. The Gli transcription factors are members of the hedgehog signaling pathway, and have been most studied in this context [1] . The Gli transcription factors coordinately regulate Gli-mediated transcription [2] ; however, Gli1 is exclusively a transcriptional activator, whereas Gli2 and Gli3 can function as either transcriptional activators or repressors [3, 4] . Hedgehog signaling activates Gli1 and Gli-mediated transcription, and because Gli1 is a target of Gli-mediated transcription, increases expression of Gli1. In addition to hedgehog signaling, expression of Gli1 and activation of Gli-mediated transcription are also induced by other signaling pathways, including TGFb and Ras [5, 6] . The TGFb stimulation of Gli1 transcription is SMAD3 mediated and independent of hedgehog signaling [5] . Oncogenic Ras also upregulates Gli1 expression and transcriptional activity independently of hedgehog signaling through MAPK/ERK and/or AKT/PI3K [7, 8] . Therefore, Gli1 and Gli-mediated transcription can be up-regulated by several signaling pathways known to be important in the development and progression of cancer.
Gli1 is transforming in rat kidney epithelial cells (i.e., RK3E cells) immortalized with adenovirus E1A [9] . In basal cell carcinomas, medulloblastomas and rhabdomyosarcomas, Gli1 is overexpressed as a result of constitutive activation of hedgehog signaling by mutations of hedgehog pathway members. This aberrant hedgehog signaling and resultant increase in Gli1 and Gli transcriptional activity drives the genesis of these cancers [10] . In other types of cancer, including carcinomas of the pancreas and prostate, mutations of hedgehog pathway members are rare; instead, Gli1 is up-regulated by either hedgehog ligand dependent or other hedgehog ligand-independent mechanisms [11] [12] [13] [14] [15] [16] . In these cancers, Gli1 and Gli-mediated transcription have been shown to be important in cancer cell growth and survival both in vitro and in xenograft models [12, 13, 15, [17] [18] [19] . Gli1 is also reported to promote invasion and metastasis in prostate cancer and melanoma [12, 20] .
In breast cancer, Gli1 is overexpressed in 40-100% of cancers [16, [21] [22] [23] . Gli1 is believed to be up-regulated by both hedgehog ligand dependent (i.e., overexpression of hedgehog ligand) and ligand independent (e.g., silencing of Ptch1 by promoter methylation) hedgehog signaling, as well as hedgehog independent mechanisms (e.g., Ras, TGFb) [5, 16, [21] [22] [23] [24] . Additionally, breast cancer stem cells, characterized by the cell surface phenotype CD44
? CD24 -/low and tumor initiating capacity, were found to express Gli1 at higher levels than other cancer cells [25] .
The prognostic and functional significance of Gli1 in breast cancer has been less extensively explored. In this report, we identify a positive association between expression of Gli1 and estrogen receptor a (ERa) in breast cancer cell lines, as well as a differential effect of Gli1 on the growth of ERa-positive versus ERa-negative breast cancer cells. We then correlate these in vitro findings with expression of Gli1 in breast cancer tissues and report a prognostic role for Gli1 in breast cancer and specifically in ERa-negative breast cancers.
Methods

Cell line maintenance
The human breast cancer cell lines MDA-MB-361, T47D, MCF7, BT474, and Hs578T were obtained from the American Type Culture Collection (Manassas, VA). MDA-MD-231 cells were a kind gift of Dr. Danny Welch. These breast cancer cell lines are classified into two major groups-ERa-positive (MDA-MB-361, T47D, MCF7, and BT474) and ERa-negative (MDA-MB-231 and Hs578T). MDA-MB-231, T47D, and MCF-7 were established from the pleural effusions of patients with metastatic breast cancer [26] . MDA-MB-361 was derived from a brain metastasis of breast cancer [27] . BT474 was isolated from a primary invasive ductal carcinoma [26] . Hs578T was derived from a carcinosarcoma of the breast [28] . MDA-MB-231, MDA-MB-361, MCF7, T47D, and BT474 are all tumorigenic in nude mice, while Hs578T is non-tumorigenic [28, 29] Among the cell lines used in this study, MDA-MB-231 is the most invasive in vitro and the most metastatic in xenograft animal models [26] . Hs578T has a moderate capability for invasion without metastatic potential [26] . MDA-MB-361, MCF7, and T47D are weakly invasive and rarely shown to be metastatic as xenografts [26, [30] [31] [32] [33] .
MCF7, MDA-MB-231, Hs578T, and MDA-MB-361 were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS). T47D and BT474 were cultured in RPMI 1640 medium containing 10% FBS.
Quantitative, reverse transcription PCR After RNA extraction, all samples were subjected to DNase pretreatment prior to cDNA synthesis (High-Capacity cDNA Reverse Transcription kit, Applied Biosystems). Primer and probe sets for estrogen receptor (ER)a, Gli1, and Ribosomal protein large 0 (RPLP0) were purchased as proprietary TaqMan Ò Gene Expression Assays-onDemand TM from Applied Biosystems (Hs01046816_m1, Hs00171790_m1, and Hs99999902_m1, respectively). Gene assays were performed using TaqMan Ò Universal PCR Master Mix (Applied Biosystems) and primer/probe sets for each target. Fluorescent signal data were collected by the ABI Prism 7700 Sequence Detection System and the log-linear phase of amplification was monitored to obtain C T values. RPLP0 was used as the internal reference. Relative expression values were calculated using the DDC T method.
Estrogen and ERa antagonist treatment of ERa-positive cell lines
For estrogen treatment, the maintenance medium was removed 2 days after plating and replaced with phenol redfree and serum-free DMEM for 24 or 48 h. The cells were then cultured in phenol red-free DMEM containing 0.5% charcoal-stripped FBS with 17b-estradiol (Steraloids Inc.) in ethanol for 48 h. For treatment with the ERa-antagonist methyl-piperidino-pyrazole (MPP) (Tocris Bioscience), 1.0 lM MPP in 95% ethanol was added to the medium 1 h before estrogen treatment. The cells were harvested for RNA extraction.
RNA interference
Lentiviral supernatants were prepared by transfection of 293T with pLKO.1-puro containing each of two shRNAs targeting human GLI1 (TRCN0000020484, TRCN0000020488; Mission shRNA plasmid DNA, Sigma-Aldrich) or a non-targeting control (NT) shRNA (Sigma-Aldrich) and the packaging plasmids pCMV-GagPol and pCMV-VSVg (gifts of Dr. Mike Ruppert). Lentiviral supernatants were collected at 48 h post-transfection and were used to transduce MCF7, MDA-MB-361, Hs578T, and MDA-MB-231 cells according to the vendor's recommended protocols followed by selection in puromycin (Cellgro) for at least 3 days. Silencing of Gli1 was confirmed by immunoblots and/or quantitative, reverse transcription PCR.
Western blot analysis
Cells were lysed in the presence of 50 mM Tris-HCl at pH 7.4, 2 mM dithiothreitol, 1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 7X protease inhibitor cocktail (Roche). The protein concentration was measured by the BCA Protein Assay (Pierce). Fifty micrograms of total protein from each sample was resolved on 4-15% gradient gels (Biorad Laboratories) and transferred to nitrocellulose membranes. Ten micrograms total protein of a lysate of F9 cells (Santa Cruz Biotechnologies), a teratocarcinoma cell line with very high Gli1 expression, was used as a positive control. Membranes were blocked with 5% dry milk in 0.1% PBS-T, followed by incubation with an immunoaffinity purified, rabbit, polyclonal antibody raised against residues 410-427 of human Gli1, a gift of Dr. Mike Ruppert [34] , at 1:2,500 dilution at 4°C overnight. Secondary detection was achieved using an anti-rabbit horseradish peroxidase labeled secondary antibody (1:5,000 dilution, Biorad) and Supersignal West Femto ECL reagent (Pierce). 
Immunohistochemical staining and assessment
For immunohistochemical staining of formalin-fixed, paraffin-embedded tissue microarrays, 5 lM sections were deparaffinized in xylene, followed by hydration in graded alcohols. The immunostaining procedure for Gli1 was similar to a previously described protocol [35] . In brief, 5 lM thick sections were incubated in 3% H 2 O 2 in methanol for 30 min at room temperature, followed by incubation in primary goat polyclonal anti-Gli1 antibody (1:100; N-16, sc-6153; Santa Cruz Biotechnology) overnight at 4°C. Secondary detection was achieved by incubation in a polymer-based secondary detection reagent (Histofine Simple Stain Max PO, Nichirei Co., Ltd.) for 30 min at room temperature. Diaminobenzidine tetrachloride (Biogenex) was used as the chromogen. The specificity of the staining was verified by specific staining of pancreatic islets in formalin-fixed, paraffin-embedded pancreatic tissues. Pancreatic islets cells have more active hedgehog signaling and higher expression of several pathway members, including Gli1, than surrounding acinar and ductal cells [36, 37] . Negative controls consisted of histologic sections processed without the addition of primary antibody. After immunostaining, sections were counter stained with hematoxylin.
Immunostaining for ErbB2, p53, ER, PR, and Ki67 proceeded as previously described [38, 39] . Briefly, immunostaining for ER, PR, and Ki-67 required low temperature antigen retrieval with enzymatic pretreatment (0.1% trypsin) followed by incubation in 10 mM citrate buffer, pH 6, for 2 h at 80°C. No antigen retrieval was required for ErbB2 and p53. The antibodies used were antiErbB2 (clone 3B5, Oncogene Research Products, San Diego, CA; 0.25 lg/ml), anti-p53 (clone BP53.12, Oncogene Research Products, Inc., San Diego, CA; 0.25 lg/ml), anti-ER (clone ER88, Biogenex, San Ramon, CA, 0.33 mg/ ml total protein), anti-PR (clone PR88, Biogenex, San Ramon, CA, 0.33 mg/ml total protein), and anti-Ki67 (clone MIB-1, Biogenex, San Ramon, CA, 0.37 mg/ml total protein). Secondary detection was achieved using a biotinylated secondary antibody, a streptavidin-horseradish peroxidase complex (Ultra Streptavidin Detection System, Signet Laboratories) and diaminobenzidine tetrachloride as the chromogen.
The intensity of cancer cell membrane immunostaining for ErbB2 and intensity of cytoplasmic and nuclear staining for Gli1 were scored separately on a scale of 0 (no staining) to 4? (strongest possible intensity), and the percentage of cells staining at each intensity was estimated. The proportion of cells at each intensity was multiplied by the corresponding intensity value and these products were added to obtain an immunostaining score (immunoscore) ranging from 0 to 4 [38, 39] . For ER, PR, p53, p27
Kip1 , Ki67, and Gli1, the percentage of cancer cells with nuclei that stained positively at any intensity was determined. The mean of the immunostaining values of replicate tissue samples for each cancer on the two tissue microarrays was used for data analysis.
Data analysis
Correlation of expression of ERa and Gli1 in cell lines was assessed by Pearson's correlation co-efficient. Gli1 expression levels by quantitative, real-time PCR were compared between groups by Student's t-test with Welch's correction. Cell growth (i.e., absorbance values) was compared between groups by the Mann-Whitney test.
For immunohistochemical analysis, breast cancers with more than 2% of nuclei staining for Gli1 were designated as Gli1-positive. Those cancers with 2% or less of nuclei that were positive for Gli1 were designated as Gli1-negative. Cancers were considered ERa-positive or PR-positive with 10% or more positive nuclei and ErbB2-positive with 10% or more cells with strong (3? or 4?) membrane staining, similar to the criterion for strong expression (3?) utilized by the Hercept-Test (Dako) [40] . For comparison of ERa with total cellular Gli1, the immunoscores for cytoplasmic and nuclear Gli1 were summed to arrive at a value for total Gli1. Comparison of the percentage of cells positive for ERa, PR, Ki-67 and p53, ErbB2 immunoscores, and tumor size between Gli1-positive and Gli1-negative cancers was accomplished using the MannWhitney test. Numbers of cases with positive lymph nodes and clinical stage I disease were compared between Gli1-positive and Gli1-negative cancers using Fisher's exact test. Cause-specific overall survival was defined as the time from the date of diagnosis to the date of death due to breast cancer. Patients who were alive at the date of last contact or died from a disease other than breast cancer were censored at the date of last contact. The relationship between Gli1 nuclear expression and survival was examined by KaplanMeier curves [41] . Differences in overall survival functions were assessed using the log-rank test. Stepwise Cox regression was used to examine multivariate predictors of survival stratified by ERa status. For all analyses, a P value of \0.05 was deemed statistically significant.
Results
Expression of Gli1 correlates with expression of ERa in breast cancer cell lines
We have previously demonstrated that Gli1 is expressed at a higher level in breast cancer cell lines in comparison with MCF10A cells, which are derived from benign breast [21] . Next, we examined the relationship between the level of expression of ERa and Gli1 mRNA in four ERa-positive breast cancer cell lines, as measured by quantitative RT-PCR (QRT). There was a strong positive correlation (r = 0.999, P \ 0.001) between expression of ERa and Gli1 mRNA (Fig. 1a) . The Gli1 protein levels reflected the Gli1 mRNA levels in that Gli1 protein expression is highest in MDA-MB-361 cells and lower in the other ERapositive cell lines (Supplemental Data, Figure S1 ), similar to the pattern found for Gli1 mRNA in these cell lines (Fig. 1a) .
Estrogen up-regulates Gli1 expression via ERa
Estrogen has been reported to regulate Gli1 expression [42, 43] . Therefore, to investigate a possible explanation for the correlation between Gli1 and ERa expression, we treated several ERa-positive cell lines with estrogen and determined the effect on Gli1 expression by QRT. In MCF7 cells, treatment with 17b-estradiol for 48 h caused a dosedependent increase in Gli1 mRNA (Fig. 1b) . Treatment of MCF7, MDA-MB-361 (361), and T47D ERa-positive cell lines with 1 nM 17b-estradiol for 48 h resulted in a significant increase in Gli1 mRNA in MCF7 (3.1-fold, P = 0.018) and 361 cells (2.7-fold, P = 0.010), but not in T47D cells (Fig. 1c) . Therefore, estrogen stimulates expression of Gli1 in some ERa-positive cell lines, but not others. In order to determine whether the estrogen-induced increase in Gli1 is mediated through ERa, MCF7 breast cancer cells were pretreated with an ERa specific inhibitor, MPP, prior to administration of 1 nM 17b-estradiol for 48 h. In the presence of MPP, estrogen no longer increased expression of Gli1 (P = 0.021, Fig. 1d ). These results confirm and expand on a prior report indicating that estrogen induces expression of Gli1 through ERa in MCF7 cells [43] .
Glil1 promotes cell growth and survival in ERa-negative cell lines Gli1 has previously been reported to promote cell survival and growth in several cancer types [12, 19, 44, 45] . In order to assess its role in mediating the growth of ERa-positive and ERa-negative breast cancers, expression of Gli1 was silenced by RNA interference in two ERa-positive (MCF7 and 361) and two ERa-negative (MDA-MB-231 and Hs578T) breast cancer cell lines. The cells were transduced to express two different shRNAs recognizing Gli1 as well as an shRNA that does not recognize any human genes (non-targeting negative control (NT)). Decreased expression of Gli1 by at least 60% compared to the NT control was confirmed by QRT and WB in each cell line (Fig. 2a,  b) . The number of viable cells present was measured by MTT assay after the NT control cells approached confluence, which was at day 5 for the rapidly growing, ERanegative MDA-MB-231 (231) and Hs578T cells, and day 7 and day 9 for the ERa-positive MCF7 and 361 cells, respectively. Reduction of Gli1 had no effect on the growth of MCF7 cells. There was a modest reduction of growth of 361 cells (9 and 24% reduction with two different shRNAs targeting Gli1, P = 0.003 and P \ 0.001, respectively) (Fig. 2c) . In contrast, silencing of Gli1 caused a marked reduction in growth in both 231 (77 and 83% reduction with two different shRNAs, P \ 0.001 for each) and Hs578T (63 and 67% reduction with two different shRNAs, P = 0.002 for each) cells. These results suggest that Gli1 has a greater impact on cell growth and/or survival of ERanegative than ERa-positive breast cancers.
Nuclear localization of Gli1 is present in 31% of breast cancers and is associated with ERa expression and absence of nuclear localization of p53
In order to determine whether our in vitro findings, specifically a relationship between ERa and Gli1 expression and function, are reflected in the expression patterns and behavior of breast cancers in vivo, we assessed Gli1 expression in breast cancer tissues and its impact on patient outcome. Two tissue microarrays containing tissue cores representing 171 infiltrating ductal carcinomas of the breast were immunostained for Gli1. Expression of Gli1 in cancer epithelial cells was primarily cytoplasmic, but there was also nuclear staining in a subset of breast cancers. Cytoplasmic expression was detected in 95% (162/171) of breast cancers. In 31% (53/171) of cancers, there was nuclear localization in addition to cytoplasmic expression of Gli1, suggesting Gli1 transcriptional activation in this subset. Nuclear localization ranged from relatively infrequent (present in 3% of cells) to extensive (present in 80% of cells) (Fig. 3a-d) .
Most of these cancers were also immunostained for the presence of ERa (n = 149), PR (n = 149), p53 (n = 154), ErbB2 (n = 156), and Ki67 (n = 150). As nuclear localization of Gli1 is likely a better indicator of Gli1 transcriptional activity than cytoplasmic Gli1, we focused our analyses on nuclear staining. We compared the presence of these biomarkers in cancers with nuclear localization of Gli1 (hereafter referred to as Gli1-positive cancers) with those without nuclear localization of Gli1 (referred to as Gli1-negative cancers). Gli1-positive cancers had a higher expression of ERa (P = 0.027) and a lower level of nuclear localization of p53 (P = 0.017) (Fig. 3e) . The rate of proliferation (i.e., percentage of cells with Ki67 labeling) was lower in Gli1 positive cancers, but this difference was of borderline significance (P = 0.060) (Fig. 3e) . There was no significant difference in PR or membrane expression of ErbB2. When comparing ERa-positive (n = 89) and ERa-negative cancers (n = 60), ERa-positive cancers were more likely to also be Gli1-positive (P = 0.033) (Fig. 3f) . The percentage of ERa positive cells was also higher in breast cancers with high total cellular Gli1 (i.e., the sum of the immunoscores for cytoplasmic and nuclear Fig. 3 Gli1 in ERa-positive and ERa-negative breast cancers. a-d There was variability in the staining pattern of infiltrating ductal carcinomas of the breast for Gli1. In some cancers, expression was both cytoplasmic and nuclear (arrowheads) (a). In others, expression was primarily or exclusively cytoplasmic (b), or primarily nuclear (arrowheads) (c). In 8 cancers, there was no nuclear or cytoplasmic Gli1 expression (d). For a-d, magnification is 2009, scale bar = 40 lM. e Cancers with Gli1 nuclear staining (Gli1-positive, n = 53) and without nuclear staining (Gli1-negative, n = 118) were compared for the percentages of cells positive for ERa, PR, p53, Ki-67 and membrane expression of ErbB2 (immunoscore). Asterisks indicate statistical significance for ERa (P = 0.027) and p53 (P = 0.017). f A comparison of the percentage of cancers which were Gli1-positive among ERa-positive (n = 89) and ERa-negative (n = 60) breast cancers was significantly different (P = 0.033). g A comparison of tumor size and the number of cases with lymph node metastases or in clinical stage I at the time of diagnosis was not different between Gli1-positive and Gli1-negative cancers. h The Kaplan-Meier estimate was used to compare cause-specific survival (i.e., death due to cancer) in women with Gli1-positive (n = 45) and Gli1-negative (n = 94) cancers. The log-rank test indicated there was no significant difference Gli1) than those with low total cellular Gli1 (using the mean of total cellular Gli1 as the cut-off for high vs. low) (55 vs. 40%, respectively, P = 0.035) (data not shown). This suggests that there is a positive association between ERa and total cellular Gli1 expression, and not just nuclear localization of Gli1.
The half-life of wild type p53 is usually too short to allow sufficient accumulation in the nucleus for detection by immunohistochemistry, and immunohistochemical detection of p53 is considered to be indicative of a mutant p53 protein with a longer half-life [46] . Therefore, our data indicate that Gli1-positive cancers are less likely to have a mutant p53 than are Gli1-negative cancers. There was no significant difference in mean tumor size, the number of cancers with lymph node metastases, or the number of cancers in clinical stage I at the time of diagnosis in Gli1-positive versus Gli1-negative cancers (Fig. 3g) . We obtained sufficiently detailed survival information for 139 cancers to compare cause-specific survival (i.e., death due to cancer) in women with Gli1-positive (n = 45) versus Gli1-negative (n = 94) cancers (Fig. 3h) , and no difference was observed. ERa-positive cancers have lower rates of proliferation, lower rates of p53 mutation, lower stage of disease and a better overall survival than ERanegative cancers [47, 48] . Therefore, we considered the possibility that the relationship between Gli1 and ERa may explain the lower rate of p53 mutation and borderline lower rate of proliferation in Gli1-positive cancers and may be obscuring an effect of nuclear localization of Gli1 on survival. In order to address this, we analyzed nuclear localization of Gli1 in ERa-positive and ERa-negative cancers separately.
Nuclear localization of Gli1 predicts a poorer survival in ERa-negative, but not ERa-positive, breast cancers Among ERa-positive cancers, there was no significant difference in expression of ERa, PR, p53, erbB2, or Ki67 in Gli1-positive (n = 34) versus Gli1-negative (n = 55) cancers (Fig. 4a) . There was also no significant difference in tumor size, lymph node status, the number of cancers in clinical stage I, or in cause-specific survival in Gli1- Fig. 4 Nuclear localization of Gli1 in ERa-positive breast cancers. a In ERa-positive breast cancers, there was no significant difference in expression of ERa, PR, p53, Ki67 or ErbB2 in Gli1-positive (n = 34) and Gli1-negative (n = 55) cancers. b In ERa-positive breast cancers, a comparison of tumor size and the number of cases with lymph node metastases or in clinical stage I at the time of diagnosis was not different between Gli1-positive and Gli1-negative cancers. c In ERapositive breast cancers, the Kaplan-Meier estimate was used to compare cause-specific survival (i.e., death due to cancer) in women with Gli1-positive (n = 30) and Gli1-negative (n = 46) cancers. The log-rank test indicated there was no significant difference. d Causespecific survival was compare in only those ERa-positive breast cancers which were treated with tamoxifen. There was no difference in survival in Gli1-positive (n = 15) versus Gli1-negative cancers (n = 28) positive versus Gli1-negative cancers (Fig. 4b, c) . It has been previously suggested that Gli1 may mediate resistance to tamoxifen or other estrogen antagonists in the treatment of ERa-positive breast cancers [49] . In order to assess a possible effect of Gli1 in mediating resistance to tamoxifen in this group of cancers, cause-specific survival was compared in those women with ERa-positive cancers treated with tamoxifen (n = 43) that were Gli1-positive versus Gli1-negative, and no significant difference was observed (Fig. 4d) .
Among ERa-negative cancers, there was also no significant difference in ERa, p53, PR, Ki67, ErbB2, or tumor size in Gli1-positive (n = 13) versus Gli1-negative (n = 47) cancers (Fig. 5a, b) . Unlike ERa-positive cancers, those ERa-negative cancers with nuclear Gli1 were more likely to be lymph node positive, but this difference did not reach statistical significance (P = 0.122). In addition, none of the ERa-negative cancers with nuclear Gli1 were in clinical stage I at the time of presentation, whereas, 10% of ERa-negative, Gli1-negative cancers were clinical stage I (Fig. 5b) . These lymph node and clinical stage data suggest a more aggressive clinical course for ERa-negative, Gli1-positive cancers than ERa-negative, and Gli1-negative cancers. In accordance with this, cause-specific survival was significantly poorer in the ERa-negative, Gli1-positive cancers (P = 0.005) (Fig. 5c) .
In a multivariable model controlling for stage at diagnosis and ErbB2 expression, those women with ERa-negative, Gli1-positive cancers had a significantly poorer cause-specific survival (hazard ratio = 6.89; 95% Fig. 5 Nuclear localization of Gli1 in ERa-negative breast cancers. a In ERa-negative breast cancers, there was no significant difference in expression of ERa, PR, p53, Ki67 or ErbB2 in Gli1-positive (n = 13) and Gli1-negative (n = 47) cancers. b In ERa-negative breast cancers, a comparison of tumor size and the number of cases with lymph node metastases or in clinical stage I at the time of diagnosis was not different between Gli1-positive and Gli1-negative cancers. c In ERa-negative breast cancers, the Kaplan-Meier estimate was used to compare cause-specific survival (i.e., death due to cancer) in women with Gli1-positive (n = 10) and Gli1-negative (n = 41) cancers. The log-rank test indicated a significant difference (P = 0.005). d Cause-specific survival was compare in triple negative breast cancers. There was a statistically significant difference in survival in Gli1-positive (n = 7) versus Gli1-negative cancers (n = 27) (P = 0.003) confidence interval = 1.97, 24.14) compared to ERa-negative, Gli1-negative cancers (Table 2) . Among ERa-positive cancers, there was no significant relationship between cause-specific survival and Gli1-positivity (P = 0.58) ( Table 2) . Additionally, pathologic stage was predictive of survival in both ERa-positive and ERa-negative cancers, and ErbB2 expression was predictive only in ERa-negative cancers (Table 2) . Those ERa-negative cancers that were also triple negative [i.e., ER-negative, PR-negative (\10% positive cells) and without over-expression of ErbB2 (\10% of cells with strong membrane staining)] were identified (n = 34). In women with triple negative cancers, those with Gli1-positive cancers also exhibited a poorer cause-specific survival than those with Gli1-negative cancers (P = 0.003) (Fig. 5d) . These data suggest that nuclear localization or activity of Gli1 in ERa-negative breast cancers, including triple negative cancers, is detrimental to clinical outcome and has a greater impact than in ERa-positive cancers.
Discussion
Our finding that nuclear localization of Gli1 is higher in ERa-positive breast cancers is in accordance with a prior analysis of 52 breast cancers immunostained for Gli1 [23] . We also provide data indicating that estrogen induces expression of Gli1 in ERa-positive breast cancer cell lines, which may contribute to the positive association between ERa and Gli1 observed in both breast cancer cell lines and tissues. Our results expand on a prior study, which was limited to MCF7 cells [43] , by demonstrating that estrogen induces Gli1 expression in several, but not all, ERa-positive breast cancer cell lines. In support of this, not all ERapositive breast cancers in our study demonstrated nuclear localization of Gli1 (62% of cancers without nuclear localization of Gli1) or Gli1 in the cytoplasm (5% of cancers without cytoplasmic or nuclear Gli1). In the prior study of MCF7 cells, estrogen-induced expression of both Gli1 and sonic hedgehog ligand (Shh), and treatment with Shh stimulated Gli1 expression, suggesting that estrogen induced the expression of Gli1 by ligand-dependent activation of autocrine hedgehog signaling [43] . Other investigators, however, have found that most breast cancer cell lines tested, including MCF7, do not respond to Shh ligand by activation of hedgehog signaling or an increase in Gli1 expression [22] . This raises the possibility that estrogen may increase Gli1 through a hedgehog ligand-independent mechanism, such as estrogen-induced activation of MAPK signaling [50] ; MAPK has been shown to stabilize Gli1 protein and increase Gli1 activity and expression [6, 8] .
It also has been reported that Gli1 induces estrogenindependent proliferation and promotes G1/S phase transition in ERa-positive breast cancer cell lines, raising the possibility that Gli1 may promote estrogen-independent growth and resistance of ERa-positive breast cancers to anti-estrogen therapies [49] . Our data do not support such a role for Gli1 in ERa-positive breast cancers. In our cohort of ERa-positive breast cancers, there was no difference in cancer-specific survival in Gli1-positive versus Gli1-negative cancers. Among ERa-positive breast cancers that were treated with tamoxifen, nuclear localization of Gli1 also failed to predict a poorer cancer-specific survival, suggesting that Gli1 has no impact on response to antiestrogen therapy.
Although nuclear localization of Gli1 is higher in ERapositive than ERa-negative breast cancers, nuclear Gli1 predicted a poor prognosis only in ERa-negative cancers in our cohort, suggesting that cell context and concurrent signaling activity direct the functional effect of Gli1-mediated transcription. In addition, the ERa-negative breast cancer cell lines that we tested are more dependent on the presence of Gli1 for growth and survival in vitro than are the ERa-positive cell lines. However, in the breast cancer tissues, we found no evidence that Gli1 promoted the growth of either ERa-negative or ERa-positive breast cancers in that there was no difference in tumor size or the rate of proliferation in Gli1-positive versus Gli1-negative cancers. Our prognostic data suggest that, rather than influence the growth of the primary tumor, Gli1 is most important for those processes that result in death, i.e., cancer recurrence, invasion, and metastasis, in ERa-negative breast cancers. Our findings require confirmation in additional breast cancer cohorts.
Although the molecular mechanisms underlying a potential difference in Gli1 function in ERa-positive and ERa-negative breast cancers remains to be elucidated, differences in Gli1 expression and function have been demonstrated previously in different breast cancer cell populations-those cancer cells with a cancer stem cell phenotype versus those lacking this phenotype. Gli1 expression is higher in breast cancer stem cell populations, characterized by the cell surface phenotype CD44
? CD24
-/ low , than in tumor cell populations lacking this marker profile [25, 51] . Additionally, breast cancer cells with the CD44 ? CD24 -/low phenotype are more dependent upon Gli1-mediated transcription for cell growth and survival than those cells without the CD44
? CD24 -/low phenotype [25, 51] . Cancer stem cells are a subpopulation of cancer cells that are believed to be responsible for the development, recurrence, and heterogeneity of tumors [52] . Additionally, increasing evidence indicates that cancer cells with the capability of metastasizing have a stem cell phenotype [53] [54] [55] . Therefore, the role of Gli1 in breast cancer may be in maintaining the viability and function of cells with a stem cell phenotype and thereby promoting the ability of these cells to generate tumor recurrence and metastases. In support of this, silencing of Gli1 expression in ERa-negative breast cancer cell lines was shown to reduce their invasiveness [45] .
One category of ERa-negative breast cancers, the basallike subtype, are enriched in CD44
? CD24 -/low stem cells [56, 57] . Other ERa-negative subtypes may also be enriched in Gli1 dependent cancer stem cells and this may contribute to the greater functional impact of Gli1 in ERanegative breast cancers. We also evaluated the prognostic role of Gli1 in triple negative breast cancers, which are those cancers that are negative for ERa, PR, and ErbB2. We found that nuclear localization of Gli1 also predicts a poor prognosis in this ERa-negative subgroup. Triple negative and basal-like breast cancers are distinct molecular classes of breast cancer with a high degree of overlap. Basal-like breast cancers are also negative for ERa, PR, and ErbB2 but are additionally characterized by expression of markers of basal and myoepithelial cells, such as basal cytokeratins and vimentin [58] . The identification of molecules, such as Gli1, that may promote progression and serve as therapeutic targets in the triple negative or basallike subtypes is particularly important as the usual therapies targeted to ERa and ErbB2 are not effective.
Additional evidence that Gli1 is functionally important in breast cancers with an ERa-negative, basal-like phenotype is the finding that Gli1 induces ERa-negative, basallike breast cancers. Transgene expression of Gli1 in the mouse mammary gland, under the regulation of the mouse mammary tumor virus promoter, resulted in the development of mammary gland cancers that are ERa-negative and express vimentin and basal keratins indicative of a basallike subtype breast cancer [59] . These Gli1-induced cancers also contained a population of stem/progenitor cells that expressed the progenitor cell markers keratin 6 and Bmi-1.
Our data also indicate an inverse relationship between nuclear localization of Gli1 and p53, which when detectable by immunohistochemistry suggests the presence of a mutated p53 protein. This inverse relationship may be simply a result of the positive association between nuclear localization of Gli1 and ERa-positive breast cancers, which commonly lack mutated p53. However, it has been demonstrated that in neural progenitor cells, wild type p53 inhibits the activity, nuclear localization and levels of Gli1 and in turn, Gli1 represses p53, establishing an inhibitory loop [60] . Gli1 was also shown to inhibit the nuclear accumulation and transcriptional activity of wild type p53 in murine embryonic fibroblasts [61] . Therefore, an inverse relationship between wild type p53 and Gli1 exists. Whether such a relationship also exists between mutated p53 and Gli1 and contributes to the inverse relationship identified in the breast cancer tissues is not known.
In summary, our data indicate that Gli1 expression and nuclear localization is greater in ERa-positive breast cancers. However, they also indicate that Gli1 has a greater functional effect in ERa-negative cancers, where it is important for cell growth or survival and its nuclear localization predicts a poorer clinical outcome.
